Trials / Unknown
UnknownNCT04174612
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
A Phase 3, Prospective, Randomized Multi-center Intervention Trial of Early Intensification in AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance: A MYNERVA-GIMEMA Study
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 172 (estimated)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, multi-center, interventional, randomized, open clinical trial for the treatment of acute myeloid leukemia with FLT3 mutations customized upon the prognostic parameter PBC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cytarabine | 100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7 |
| DRUG | Daunorubicin | 60 mg/m2/die day 1-3 |
| DRUG | Midostaurin | 50 mg/bid day 8-21 |
| DRUG | Cytarabine HD | 100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7 |
Timeline
- Start date
- 2020-04-24
- Primary completion
- 2022-12-01
- Completion
- 2025-08-01
- First posted
- 2019-11-22
- Last updated
- 2022-03-02
Locations
20 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04174612. Inclusion in this directory is not an endorsement.